Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells-Reference-Cited by-同舟云学术

Effects of Immunosuppressants on Receptor Activator of NF-κB Ligand and Osteoprotegerin Production by Human Osteoblastic and Coronary Artery Smooth Muscle Cells

Published:2001-01 Issue:1 Volume:280 Page:334-339
ISSN:0006-291X
Container-title:Biochemical and Biophysical Research Communications
language:en
Short-container-title:Biochemical and Biophysical Research Communications

Author:

Hofbauer Lorenz C.,Shui Chaoxiang,Riggs B.Lawrence,Dunstan Colin R.,Spelsberg Thomas C.,O'Brien Timothy,Khosla Sundeep

Publisher

Elsevier BV

Subject

Cell Biology,Molecular Biology,Biochemistry,Biophysics

Reference32 articles.

1. New issues in therapy after renal transplantation;Luke;N. Engl. J. Med.,1994

2. Post-transplantation bone disease: The role of immunosuppressive agents and the skeleton;Epstein;J. Bone Miner. Res.,1996

3. Tacrolimus;Spencer;Drugs,1997

4. The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK-506 on bone mineral metabolism in vivo;Cvetkovic;Transplantation,1994

5. Rapamycin: A bone sparing immunosuppressant?;Romero;J. Bone Miner. Res.,1995

Cited by 189 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Low skeletal muscle mass index is independently associated with low bone mineral density in kidney transplant recipients: a retrospective observational cohort study;Journal of Nephrology;2024-04-17

2. Changes in High Resolution peripheral Quantitative Computed Tomography in adolescents undergoing a first kidney transplantation.;2024-02-28

3. Changes in High Resolution peripheral Quantitative Computed Tomography (HR-pQCT) in teenagers undergoing a first renal transplantation between baseline and 6 months;2023-12-20

4. The Effect of PCSK9 Inhibition on the Stabilization of Atherosclerotic Plaque Determined by Biochemical and Diagnostic Imaging Methods;Molecules;2023-08-07

5. Plasma osteoprotegerin predicts adverse cardiovascular events in stable coronary artery disease: the PEACE trial;Frontiers in Cardiovascular Medicine;2023-06-14